LARTRUVO®

(Olaratumab)

Documentation

Patented
Approved 2016
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: PDGFRα
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA